Manufacturer Release 102
Guidance for : Excluding Abuse-Deterrent Formulations From the Definition of Line Extension The purpose of this guidance is to clarify how the Centers for Medicare & Medicaid Services (CMS) intends to verify if a drug is an abuse-deterrent formulation, and thus be excluded from the definition of line extension for purposes of the Medicaid Drug Rebate (MDR) program.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: November 17, 2016
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.